{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:38Z","timestamp":1792800938431,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with advanced cervical cancer complicated by renal dysfunction and severe anemia are frequently ineligible for standard platinum-based chemotherapy, creating an urgent need for effective non-platinum salvage strategies. We report a patient with FIGO stage IVB poorly differentiated cervical squamous cell carcinoma with HER2 immunohistochemistry (IHC) 2+ expression, acute kidney injury caused by malignant ureteral obstruction (serum creatinine, 793 \u03bcmol\/L), and severe anemia (hemoglobin, 47 g\/L) at presentation. After bilateral nephrostomy, the patient received PRaG 3.0, a five-component regimen comprising stereotactic body radiotherapy, adebrelimab (anti-PD-L1), disitamab vedotin (HER2-directed antibody-drug conjugate), granulocyte-macrophage colony-stimulating factor, and interleukin-2. After two cycles, both the cervical primary lesion and pulmonary metastases showed marked regression, and the best overall response was partial response. Treatment was generally manageable; the only grade 3 treatment-related adverse event was an interleukin-2-associated generalized rash, which resolved after drug discontinuation and supportive care. At the last follow-up, progression-free survival exceeded 8 months, and both nephrostomy tubes had been removed. This case suggests that PRaG 3.0 may provide clinically meaningful disease control in selected patients with advanced cervical cancer and severe comorbidities who cannot tolerate platinum-based chemotherapy. Given the single-patient nature of this report, prospective validation is required.<\/jats:p>","DOI":"10.3389\/fonc.2026.1912098","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:31:18Z","timestamp":1789533078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: PRaG 3.0 therapy for advanced cervical cancer with severe comorbidities"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinyi","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People\u2019s Hospital (The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine)","place":["Chengdu, Sichuan, China"]},{"name":"PD-1 inhibitor, Radiotherapy, and Granulocyte-Macrophage Colony-Stimulating Factor (PRaG) Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Xu","sequence":"additional","affiliation":[{"name":"PD-1 inhibitor, Radiotherapy, and Granulocyte-Macrophage Colony-Stimulating Factor (PRaG) Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwen","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People\u2019s Hospital (The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine)","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People\u2019s Hospital (The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine)","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"PD-1 inhibitor, Radiotherapy, and Granulocyte-Macrophage Colony-Stimulating Factor (PRaG) Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xing","sequence":"additional","affiliation":[{"name":"PD-1 inhibitor, Radiotherapy, and Granulocyte-Macrophage Colony-Stimulating Factor (PRaG) Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"PD-1 inhibitor, Radiotherapy, and Granulocyte-Macrophage Colony-Stimulating Factor (PRaG) Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehong","family":"Kong","sequence":"additional","affiliation":[{"name":"PD-1 inhibitor, Radiotherapy, and Granulocyte-Macrophage Colony-Stimulating Factor (PRaG) Center, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e30","article-title":"Recent breakthroughs in the management of locally advanced and recurrent\/metastatic cervical cancer","volume":"35","author":"Garc\u00eda","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Ctr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1075.63136","article-title":"Aggressive approach in a case of cancer cervix with uremia","volume":"16","author":"Janaki","year":"2010","journal-title":"Indian J Palliat Car"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-316","article-title":"The incidence of venous thromboembolism in cervical cancer: a nationwide population-based study","volume":"5","author":"Tsai","year":"2012","journal-title":"BMC Res Notes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011000.pub3","article-title":"Palliative interventions for controlling vaginal bleeding in advanced cervical cancer","author":"Eleje","year":"2015","journal-title":"Cochrane Db Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2021.22.4.1211","article-title":"Factors affecting survival outcome after percutaneous nephrostomy as palliative urinary diversion in obstructive uropathy due to advance cervical cancer patients","volume":"22","author":"Noegroho","year":"2021","journal-title":"Asian Pac J Cancer P"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200409000-00004","article-title":"Chemoradiation with gemcitabine for cervical cancer in patients with renal failure","volume":"15","author":"Cetina","year":"2004","journal-title":"Anti-Cancer Drug"},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/0973-1075.53510","article-title":"Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series","volume":"15","author":"Mishra","year":"2009","journal-title":"Indian J Palliat Car"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/ms9.0000000000003620","article-title":"Anemia and hematocrit decline in cervical cancer: unveiling clinical consequences and management strategies","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12905-021-01185-9","article-title":"Prevalence and associated factors of baseline anemia among cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia","volume":"21","author":"Wassie","year":"2021","journal-title":"BMC Womens Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"27630","DOI":"10.1038\/s41598-024-75937-6","article-title":"Hematological changes in women with cervical cancer before and after cancer treatment: retrospective cohort study","volume":"14","author":"Berta","year":"2024","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13909","article-title":"Waikato Environment for Knowledge Analysis (WEKA) as a data analysis method identifying potential hematological parameters for early diagnosis of cervical cancer","volume":"39","author":"Chiu","year":"2025","journal-title":"In Vivo"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(03)00347-x","article-title":"A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma","volume":"56","author":"Duenas-Gonzalez","year":"2003","journal-title":"Int J Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1179554918779587","article-title":"Bevacizumab eligibility in patients with metastatic cervical cancer: a retrospective review","volume":"35","author":"Skelton","year":"2017"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00780-3","article-title":"Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma","volume":"34","author":"Huang","year":"2021","journal-title":"Modern Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952066","article-title":"PD-1 inhibitor combined with radiotherapy and GM-CSF (PRaG) in patients with metastatic solid tumors: an open-label phase II study","volume":"13","author":"Kong","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/15330338261432537","article-title":"Evaluation of RC48-ADC in combination with PRaG regimen: an open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 study protocol)","volume":"25","author":"Xu","year":"2026","journal-title":"Technol Cancer Res T"},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e14614","DOI":"10.1200\/jco.2023.41.16_suppl.e14614","article-title":"A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1\/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors","volume":"41","author":"Xu","year":"2023"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: a synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med J Aust"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663749","article-title":"The incorporation of immunotherapy and targeted therapy into chemoradiation for cervical cancer: a focused review","volume":"11","author":"Odiase","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00972","article-title":"Comparative safety of PD-1\/PD-L1 inhibitors for cancer patients: systematic review and network meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-025-13589-z","article-title":"Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Tar"},{"key":"B33","doi-asserted-by":"publisher","first-page":"-","DOI":"10.1056\/nejmoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1200\/jco.2024.42.16_suppl.5528","article-title":"Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r\/mCC): interim results of RC48-C018","volume":"42","author":"Yuan","year":"2024"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e17534","article-title":"Efficacy and safety of disitamab vedotin combination therapy in HER2-positive advanced gynecological cancers: a multicenter retrospective analysis","volume":"43","author":"Liu","year":"2025"},{"key":"B37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","article-title":"Improved survival and tumor control with interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry","volume":"5","author":"Curti","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/jco.2025.43.16_suppl.8509","article-title":"First-in-class PD-1\/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC)","volume":"43","author":"Zhou","year":"2025"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e14500","article-title":"First-in-human study of AWT020, a bifunctional anti-PD-1\/IL-2 fusion protein, in patients with advanced cancer","volume":"43","author":"Coward","year":"2025"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.10","article-title":"The multifaceted role of CD4+ T cells in CD8+ T cell memory","volume":"16","author":"Laidlaw","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature04790","article-title":"Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells","volume":"441","author":"Williams","year":"2006","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-1322","article-title":"CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes","volume":"70","author":"Bos","year":"2010","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxag002","article-title":"Circulating T-lymphocyte subsets as biomarkers for immune checkpoint inhibitors in solid tumors","volume":"220","author":"Kong","year":"2026","journal-title":"Clin Exp Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/intimm\/dxx073","article-title":"Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with Malignant melanoma","volume":"30","author":"Takeuchi","year":"2018","journal-title":"Int Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202514982","article-title":"CD20+FCRL4+ B cells activate CD8+ T cells via MHC-I restriction in nasopharyngeal carcinoma anti-tumor immunity","volume":"13","author":"Zhang","year":"2026","journal-title":"Adv Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.3390\/ijms22158017","article-title":"Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy","volume":"22","author":"Reschke","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1912098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:31:41Z","timestamp":1789533101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1912098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":48,"alternative-id":["10.3389\/fonc.2026.1912098"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1912098","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1912098"}}